Opthea Overview

  • Status
  • Public
  • Employees
  • 8
  • Stock Symbol
  • OPT
Stock Symbol
  • Share Price
  • $1.00
  • (As of Monday Closing)

Opthea General Information


Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

Contact Information

Formerly Known As
Circadian Technologies
Ownership Status
Publicly Held
Financing Status
Primary Industry
Other Industries
Drug Discovery
Stock Exchange
Primary Office
  • Suite 0403, Level 4
  • 650 Chapel Street
  • South Yarra, Victoria 3141
  • Australia
+61 (03) 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Opthea Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.00 $1.09 $0.99 - $2.36 $337M 338M 770K -$0.10

Opthea Financials Summary

In Thousands,
TTM 31-Dec-2020 FY 2020 30-Jun-2020 FY 2019 30-Jun-2019 FY 2018 30-Jun-2018
EV 456,029 394,034 88,757 45,369
Revenue 216
EBITDA (35,794) (17,174) (25,933) (23,155)
Net Income (30,189) (11,072) (14,951) (13,093)
Total Assets 163,931 49,395 26,375 33,847
Total Debt 158 182 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Opthea Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Opthea‘s full profile, request access.

Request a free trial

Opthea Executive Team (3)

Name Title Board Seat Contact Info
Megan Baldwin Ph.D Chief Executive Officer & Managing Director
Mike Tonroe Chief Financial Officer & Company Secretary
You’re viewing 2 of 3 executive team members. Get the full list »

Opthea Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Opthea Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Opthea‘s full profile, request access.

Request a free trial